Each human cell contains at least 1000 mitochondria, each containing several copies of mitochondrial DNA. This DNA is tiny compared with the nuclear genome, and its structure and products have been fully elucidated. Whilst oxidative phosphorylation depends on the polypeptides encoded by mitochondrial DNA, it also requires a huge number of nuclear DNA products. Inherited deleterious mutations of mitochondrial DNA leading to inefficient oxidative phosphorylation have been described as 'mitochondrial disorders', with a variety of clinical presentations. When similar clinical presentations occur with no discernible mutation of mitochondrial DNA, histological and biochemical evidence is required for diagnosis. The number of these laboratoryproven inherited mitochondrial disorders is growing. It is also becoming clear that mitochondrial DNA defects can be acquired, the most common cause being therapy with highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV-1) infection. Whilst definitive diagnosis of inherited or acquired mitochrondrial dysfunction requires access to specialist laboratory techniques, routine laboratories have a role to play in the initial investigation and monitoring of these conditions.
Mitochondrial dysfunction leads to inadequate functioning of the respiratory chain and oxidative phosphorylation ( Fig. 1 ). De¢ciency in this ¢nal common pathway of adenosine triphosphate (ATP) production can lead to widespread symptoms.
Diseases of mitochondrial dysfunction may be inherited or acquired. Inherited diseases, the so-called mitochondrial disorders, may be caused by defects in either mitochondrial or nuclear DNA. Over 50 point mutations of mitochondrial DNA have been identi¢ed and associated with mitochondrial disorders. 1 The exact mutations of nuclear DNA associated with clinical disorders of mitochondrial dysfunction are largely unknown, but their existence is inferred from clinical presentation and biochemical testing of the respiratory chain. Where the exact mutation is known the relationship between genotype and phenotype is not ¢xed and the same mutation can be found in di¡erent diseases. 1, 2 The minimum prevalence of mitochondrial disorders in adults in the UK has been estimated at 6Í57 per 100 000. 3 This ¢gure does not take into account the contribution of mitochondrial dysfunction to neurodegenerative diseases such as Friedreich's ataxia, Parkinson's, Huntington's and Alzheimer's diseases. 4 The most common cause of acquired defects of mitochondrial DNA is treatment with highly active antiretroviral therapy (HAART) for human immuno -de¢ciency virus-1 (HIV-1) infection. Evidence is accumulating that nucleoside -analogue reverse transcriptase inhibitors cause depletion of mitochondrial DNA leading to unwanted side-e¡ects of therapy that are similar to the symptoms of inherited mitochondrial disorders. 5 De¢nite diagnosis of mitochondrial dysfunction relies upon a combination of clinical presentation, measurement of metabolites, histological staining of biopsies, analysis of respiratory chain function or enzyme activities and DNA studies ( Table 1 ). 6 The ragged red ¢bres on skeletal muscle biopsies stained with succinate dehydrogenase or the Gimori trichome stain result from the proliferation of faulty mitochondria. Ragged red ¢bres may be absent in children even in proven mitochondrial disorders. 7 In these cases, morphological changes characteristic of mitochondrial dysfunction can sometimes be found in brain biopsies (post-mortem) and/or liver, heart and intestinal tissues. Reduced respiratory chain activity can be demonstrated by staining biopsy tissue for cytochrome-c-oxidase or by biochemical assay of the individual complexes. Finally, mitochondrial or nuclear DNA can be analysed for mutations. The analyses involved in mitochondrial dysfunction are di¤cult both to perform and to interpret, 8, 9 and even the experts have not reached a consensus on diagnosis. 6, 10 However, patients with inherited mitochondrial disorders do not always present to experts, and patients are treated for HIV-1 infection all over the country. This paper will address the clinical presentation of mitochondrial dysfunction and the role of common laboratory tests in its investigation.
Mitochondrial DNA
The Cambridge reference sequence for mitochondrial DNA was ¢rst published in 1981. 11 The 16Í5 kb of mitochondrial DNA, less than one-hundredth the size of nuclear DNA, does not contain enough genetic information to code for all the proteins of oxidative phosphorylation, and input from the nuclear genome is required. Nuclear DNA encodes roughly 80% of the protein subunits of the respiratory chain and an unde¢ned number of regulatory polypeptides essential for the import of these polypeptides into the mitochondrion as well as for the expression of mitochondrial DNA and respiratory chain assembly and integrity ( Table 2) . Harmony between the two genomes must be maintained by other, as yet unknown, regulatory factors.
The special features of mitochondrial DNA can be summarized as follows. 12 Mitochondrial DNA contains 13 polypeptide-encoding genes and 24 RNA genes, which allows for only 1kb of non-coding DNA (the D-loop); even this region is associated with nuclear DNA interactions of transcription and translation. The coding-dense nature of mitochondrial DNA makes it more susceptible to mutations than nuclear DNA, where large non-coding regions appear to o¡er In this scheme, diagnosis depends on the identi cation of two major criteria. 6 some protection. Each cell contains at least 1000 copies of mitochondrial DNA. Usually these are all the same (homoplastic), but mutant forms may co-exist with wild-type mitochondrial DNA (heteroplastic). In heteroplastic mitochondria there is a certain threshold of mutant DNA at which dysfunction becomes evident. This threshold varies according to the particular mutation. Mitochondria, and the mitochondrial DNA they contain, are randomly segregated during cellular replication. This means that di¡erent tissues, and the cells within those tissues, can contain di¡erent proportions of mutant and wild-type DNA. Embryonic cells inherit their mitochondrial DNA from the oocyte; mitochondrial DNA mutations are, therefore, maternally inherited. HAART for the treatment of HIV-1 infection comprises a combination of nucleoside-analogue reverse transcriptase inhibitors and protease inhibitors. Zidovudine (AZT) was the ¢rst nucleosideanalogue reverse transcriptase inhibitor to be shown to a¡ect mitochondrial function through inhibition of mitochondrial DNA replication with consequent DNA depletion. 13 This e¡ect is caused by the inhibition of DNA polymerase g and is common to most nucleosideanalogue reverse transcriptase inhibitors. 5 Monitoring of mitochondrial function is now routine in patients treated with HAART.
Clinical expression of mitochondrial dysfunction
Mitochondrial dysfunction is usually expressed in tissues that have a high aerobic demand such as skeletal and cardiac muscle and neurones. Muscle and nerve cells, in common with endocrine organs, are post-mitotic tissues which means that they cannot select against cells containing faulty mitochondria. The involvement of non-post-mitotic tissue is an important feature of paediatric mitochondrial disorders. The clinical expression of mitochondrial dysfunction is best approached by examining the features of established inherited disorders and the side-e¡ects of antiretroviral therapy that have been linked to mitochondrial toxicity. Table 3 shows the inherited mitochondrial disorders known to result from defects of mitochondrial DNA. Disorders involving point mutations are maternally inherited. As translation/transcription of mitochondrial DNA is under the control of the nuclear genome, disorders involving deletions/duplications may be inherited from either parent.
Inherited mitochondrial disorders
The full names of the inherited metabolic disorders are given in Table 3 ; commonly used acronyms will be used in the text. LHON is characterized by bilateral sequential visual loss in young adulthood. The clinical features of MELAS, MERRFand NARP are described by their titles. PEO is characterized by bilateral ptosis and ophthalmoplegia, with varying degrees of muscle involvement. Kearns^Sayre syndrome comprises PEO with onset before age 20 accompanied by pigmentary retinopathy with either a cerebrospinal £uid (CSF) protein 41g/L, cerebella ataxia and/or heart block. MNGIE and Pearson's syndrome are diseases of early infancy and are examples of the clinical expression of mitochondrial dysfunction in non-post-mitotic tissues, in this case the gastrointestinal tract and bone marrow. MNGIE is characterized by prominent gastrointestinal dysmotility, PEO, peripheral neuropathy and myopathy. Pearson's syndrome consists of sideroblastic anaemia with pancytopenia and exocrine pancreatic failure. Large-scale rearrangements of mitochondrial DNA have occasionally been found in young patients with DIDMOAD or Wolfram's syndrome 2 (for full name see Table 3 ). Table 4 shows the major and minor symptoms of established mitochondrial disorders. 2 Investigation for mitochondrial dysfunction often follows the observation of several symptoms described in known mitochondrial disorders, particularly if symptoms occur in more than one tissue. An example of this is Leigh's syndrome which involves severe psychomotor delay, cerebellar and pyramidal signs, seizures, dystonia, respiratory abnormalities, poor coordination of ocular movements and recurrent vomiting. Abnormalities of mitochondrial DNA are rarely found, but enzyme analysis often shows a defect in complex IV, although complex I and II de¢ciencies have also been described. 1 Similarly, Barth syndrome, or X-linked cardioskeletal myopathy with neutropenia, has been mapped to Xq28, but there is evidence that the symptoms re£ect defective respiratory chain activity. 14 A third example of the multisystem presentation of mitochondrial dysfunction is liver disease with neurological abnormality. A high incidence of mitochondrial dysfunction has been found where these two occur together. 15 Although mitochondrial disorders usually show involvement of more than one tissue they may present with an isolated clinical feature, as in adult PEO. Single -tissue presentations are found, particularly in children. These include isolated myopathy in complex III de¢ciency, 16 cardiomyopathy secondary to de¢ciency of complexes I, III, IV, 17 and neonatal hepatic failure associated with defects of complexes I or IV or multiple enzyme de¢ciency. 15 There have been cases of respiratory chain defects presenting before 1 year of age with recurrent vomiting, chronic diarrhoea, villous atrophy and failure to thrive. 15
Antiretroviral therapy
Controversy remains over the role played by protease inhibitors in the side -e¡ects of HAART, but there is growing evidence that several of its deleterious e¡ects can be assigned to nucleoside-analogue reverse transcriptase inhibitors. 5 The incidence of these e¡ects, which are shown in Table 5 , generally increases with prolonged therapy. They are not related to plasma levels and it has been postulated that the tissue speci-¢city of the side-e¡ects of di¡erent nucleosideanalogue reverse transcriptase inhibitors is due to di¡erent levels of drug penetration. 18 Neurological symptoms occur in 10^30% patients and can be shown to be due to axonal degeneration. 5 Muscle symptoms have been reported in 17% of patients treated with AZT, although cardiomyopathy is rare. 5 The high energy demand of the renal tubules Table 3 . Square brackets denote that the clinical symptom is a minor feature of the disease. 21 Insulin resistance is often accompanied by dyslipidaemia and appears as part of the lipodystrophy syndrome. Lipodystrophy is one of the most common side-e¡ects of HAART; it occurs in 18^83% of patients. 5 There is peripheral fat loss (face, limbs and buttocks) and central fat accumulation (abdomen, breasts and dorsocervical spine). The syndrome shows similaritie s to multiple symmetrical lipomatosis, which has been found to be associated with various de¢ciencies of the respiratory chain. 22, 23 These similarities have led Brinkman and colleagues 24 to postulate that lipodystrophy in HAART is caused by the mitochondrial toxicity of nucleoside-analogue reverse transcriptase inhibitors. Hepatic side-e¡ects are associated with macro-and microvesicular steatosis and are often accompanied by lactic acidosis, which can prove fatal. 19, 20 Lactic acid levels are elevated in 12^20% of patients receiving HAART. 20 Analogy has been drawn between the sideroblastic anaemia of Pearson's syndrome and AZT-induced anaemia, leucopenia, thrombocytopenia and bone marrow failure. 18 It is less easy to envisage a common mechanism between exocrine pancreatic failure in Pearson's syndrome and didanosine -induced pancreatitis.
Laboratory tests
The wide variety of symptoms resulting from mitochondrial dysfunction means that all laboratories are likely to be faced with clinicians wanting to con¢rm or exclude this possibility.
Blood lactate
The measurement of lactate is one of the most readily available biochemical indicators of possible mitochondrial dysfunction.
Blood lactate is raised in tissue hypoxia and hypoperfusion, liver and renal failure and during treatment with drugs such as valproate and corticosteroids. Of the inborn errors of metabolism it is raised in pyruvate dehydrogenase (PDH) de¢ciency and Krebs-cycle defects as well as in mitochondrial disorders.
Zeviani and colleagues 25 stressed the role of lactate measurements as a relatively non-invasive procedure in the investigation of non-speci¢c neurological disease in children. They used an upper limit of normal for lactate of 1Í8 mmol/ L, provided that venous stasis was avoided at the point of blood collection (no tourniquet) and the assay was performed on whole blood deproteinized immediately after collection. Of 125 patients with a high plasma lactate, a mitochondrial disorder was found in 42 cases. Although some authors, looking speci¢cally at childhood diseases associated with mitochondrial DNA mutations, have suggested that plasma lactate results are not useful, 26 a review of their results and other existing data suggests that a plasma lactate of 52Í0 mmol/ L, on avenous blood sample, carries a 97% negative predictive value for a known mitochondrial mutation. 27 In routine practice it is generally accepted that a blood or plasma lactate level 43Í0 mmol/ L warrants further investigation even if the sample was taken with a tourniquet on a struggling child. 28 Lactate stress tests have been advocated for the investigation of mitochondrial disorders in adults. A reference range for serum lactate (obtained using an indwelling venous catheter) was obtained in 47 controls aged 15^72 years. The upper limit of normal after a 5-min workload of 30 W on a cycle ergometer was 2Í0 mmol/ L. The sensitivity of the lactate stress test in the diagnosis of mitochondrial myopathy in 16 patients was 94%. 29 The lactate:pyruvate ratio can be useful in the investigation of mitochondrial disorders. A lactate: pyruvate ratio of 440 is usually considered signi¢cant. 28 Pyruvate is unstable ex vivo and samples have to be deproteinized immediately after they are taken. Few laboratories will have su¤cient demand to allow the test to be performed on site. The measurement of pyruvate is rarely warranted in the absence of a raised lactate. Lactate levels are routinely monitored in patients on HAART. In our laboratory, lactate levels above 5Í0 mmol/ L are promptly communicated to the physician to allow immediate review of therapy. Lactate levels of over 10 mmol/ L carry a mortality rate of 80%. 5 The lactate:pyruvate ratio is raised in nucleoside-analogue reverse transcriptase inhibitorinduced mitochondrial dysfunction, 30 although its measurement is unnecessary in routine patient management.
Cerebrospinal uid lactate
CSF lactate is raised in meningitis, Herpes simplex encephalitis, status epilepticus and cerebral hypoxic ischaemia as well as PDH de¢ciency, biotinidase de¢ciency and mitochondrial disorders. Elevated CSF lactate can be considered another marker of mitochondrial dysfunction. Stacpoole and colleagues 31 investigated blood and CSF lactate levels in children with a proven diagnosis of an inherited mitochondrial disorder. Their control group comprised 39 patients aged 0Í03^17Í7 years. Using samples collected from an indwelling central or venous catheter, they established an upper limit of normal for plasma lactate of 1Í0 mmol/ L. The upper limit of normal for CSF lactate was established at 1Í3 mmol/ L (assuming fewer than 10 leucocytes or erythrocytes/mL). The mean plasma lactate in the 21 patients with a mitochondrial disorder was 2Í18 mmol/ L (range 0Í4^5Í5). The level of CSF lactate was higher than plasma lactate in all but one subject, with a mean value of 4Í07 mmol/ L (range 0Í9^6Í5). One of the three subjects with normal plasma lactate had an elevated CSF lactate. This may re£ect the fact that the lactate concentration in CSF is less variable than that of blood. The sensitivity of an elevated plasma lactate in the detection of a mitochondrial disorder was 86%, whilst that of an elevated CSF lactate was 90%.
A similar study established an upper limit of normal for both venous plasma and CSF lactate of 2Í4 mmol/ L. 32 Using these values, eight of 11 patients with a diagnosed mitochondrial disorder had a raised plasma lactate (sensitivity 73%) and nine of 11 had a raised CSF lactate (sensitivity 84%). In this study, two of the three patients with normal plasma lactate had an elevated concentration in their CSF. By combining elevated plasma and CSF lactates in an either/or rule, the overall sensitivity was raised to 91%.
Urine organic acids
Lactic aciduria may be evident on routine urine organic acid screening.When this is a feature of mitochondrial dysfunction it is often accompanied by the excretion of citric acid cycle intermediates. In mitochondrial disorders presenting with renal symptoms in childhood, urine lactate may be raised despite normal blood lactate and pyruvate. 15 The reduced intramitochondrial redox state caused by ine¤cient functioning of the respiratory chain has secondary e¡ects on fatty acid metabolism. Patients with mitochondrial disorders often have urine organic acid pro¢les similar to those seen in fatty acid oxidation disorders. 33 3-Methylglutaconic and ethylhydracylic acids can be found on urine organic acid screening in Barth syndrome. 14 
Ketoacidosis
A recent report describes ketoacidosis as the ¢rst presentation of MELAS in a 6-year-old. The child presented twice with ketoacidosis. On the ¢rst occasion he was hypoglycaemic. Plasma lactate was not measured during the ¢rst episode of ketoacidosis but was normal during the second. Sixteen months later he presented with a 1-day history of left-sided weakness and slurred speech and then proceeded to develop left-sided focal seizures. During this admission his plasma lactate ranged from 1Í6 to 6Í8 mmol/ L. His CSF lactate was 6Í8 mmol/ L, which led to the suggestion that CSF lactate analysis should be considered as part of the investigation of unexplained ketoacidosis. 34 Ketoacidosis is rare in patients treated for HIV-1, even in the presence of diabetes mellitus. 35 
Creatine kinase and myoglobinuria
If muscular involvement secondary to mitochondrial dysfunction is severe, myoglobinuria may be present. Munnich et al. 15 reported an infant who presented with attacks of trunk and limb hypotonia with muscle sti¡ness at the ages of 3 weeks and 3 months. Grossly elevated plasma creatine kinase was associated with myoglobinuria. Lactate and pyruvate levels were normal. The infant was found to have a de¢ciency of complex IV and died at 6 months of a terminal haemolytic uraemic syndrome.
Elevated creatine kinase is regarded as one of the hallmarks of nucleoside -analogue reverse transcriptase inhibitor-induced mitochondrial dysfunction. 5 Rhabdomyolysis has been reported in patients treated with nucleoside -analogue reverse transcriptase inhibitors. 36
Renal function tests
A review of children presenting with renal disease and later proven to be su¡ering from a mitochondrial disorder included cases of proximal tubulopathy, tubulointerstitial nephritis, nephrotic syndrome and renal failure. 15 All patients exhibited increased lactate and citric acid cycle intermediates in their urine. A recent report in this journal 37 described a boy in whom salt wasting preceded the development of other features of KSS.
Liver function tests
Individuals a¡ected by mitochondrial disorders appear particularly vulnerable to valproate -induced liver failure, and mitochondrial dysfunction should be considered in any child showing signs of valproateinduced hepatic problems. 38 Moderately elevated levels of transaminases without hyperbilirubinaemia 19, 20 accompany lactic acidosis induced by nucleosideanalogue reverse transcriptase inhibitors.
Endocrine tests
Diabetes mellitus, diabetes insipidus and hypoparathyroidism are the commonest endocrine problems associated with mitochondrial disorders but hypothyroidism, adrenocorticotrophic hormone and growth hormone de¢ciency have all been reported. 15 Insulin resistance in nucleoside-analogue reverse transcriptase inhibitor therapy is usually identi¢ed after a glucose load. 21 Insulin resistance is strongly associated with hypertriglyceridaemia and hypercholesterolaemia in the lipodystrophy syndrome. 5 There are no agreed diagnostic criteria for the lipodystrophy syndome, but a working case de¢nition has been proposed: 35 development of the characteristic abnormal adipose tissue distribution plus one or more metabolic features (fasting hyperglycaemia or glucose intolerance; elevated fasting C-peptide; fasting hyperlipidaemia).
Treatment of mitochondrial dysfunction
Most current treatments of mitochondrial disorders are intended to relieve symptoms. 39 Lactic acidosis may be managed using bicarbonate administration and dialysis. Carnitine administration may o¡set carnitine depletion caused by the secondary e¡ects of mitochondrial dysfunction on fatty acid metabolism. Standard doses of vitamins C and K, thiamine, ribo-£avin and ubiquinone (coenzyme Q10) have been tried, but the bene¢ts are not established. 40, 41 Exercise may decrease the proportion of mutant mtDNA in muscle. 42 Tricyclic antidepressants are used to combat the neurological abnormalities found in patients treated with nucleoside -analogue reverse transcriptase inhibitors. 5
Conclusion
Acquired and inherited mitochondrial dysfunction is an expanding area of interest. Whilst the diagnosis of mitochondrial disorders requires adherence to strict criteria that can be applied only in a few specialist centres, careful attention to simple tests in the routine laboratory may o¡er an early indication of impaired mitochondrial function.
